rs397514477
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_031448.6(C19orf12):c.-2C>T variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000149 in 1,613,672 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000014 ( 0 hom. )
Consequence
C19orf12
NM_031448.6 5_prime_UTR
NM_031448.6 5_prime_UTR
Scores
2
16
Clinical Significance
Conservation
PhyloP100: -0.906
Genes affected
C19orf12 (HGNC:25443): (chromosome 19 open reading frame 12) This gene encodes a small transmembrane protein. Mutations in this gene are a cause of neurodegeneration with brain iron accumulation-4 (NBIA4), but the specific function of the encoded protein is unknown. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Dec 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 19-29708415-G-A is Pathogenic according to our data. Variant chr19-29708415-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 31156.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
C19orf12 | NM_031448.6 | c.-2C>T | 5_prime_UTR_variant | 2/3 | ENST00000323670.14 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
C19orf12 | ENST00000323670.14 | c.-2C>T | 5_prime_UTR_variant | 2/3 | 2 | NM_031448.6 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000263 AC: 4AN: 152176Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
4
AN:
152176
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000803 AC: 2AN: 249206Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135206
GnomAD3 exomes
AF:
AC:
2
AN:
249206
Hom.:
AF XY:
AC XY:
1
AN XY:
135206
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461496Hom.: 0 Cov.: 31 AF XY: 0.0000151 AC XY: 11AN XY: 727042
GnomAD4 exome
AF:
AC:
20
AN:
1461496
Hom.:
Cov.:
31
AF XY:
AC XY:
11
AN XY:
727042
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000263 AC: 4AN: 152176Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74340
GnomAD4 genome
?
AF:
AC:
4
AN:
152176
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74340
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
?
AF:
AC:
1
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neurodegeneration with brain iron accumulation 4 Pathogenic:5Other:1
not provided, no classification provided | literature only | GeneReviews | - | Founder variant in Turkish population (Olgiati et al 2017); Mean age of onset is 25 yrs in persons homozygous for this variant (Hartig et al 2013). - |
Pathogenic, criteria provided, single submitter | curation | SIB Swiss Institute of Bioinformatics | May 31, 2018 | This variant is interpreted as a Pathogenic, for Neurodegeneration with brain iron accumulation 4, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PS4-Moderate => Recurrent mutation observed in multiple unrelated patients (PMID:22584950,23278385,21981780,25592411,23166001,23436634). PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:21981780,23436634). PP1-Strong => PP1 upgraded in strength to Strong (PMID:23278385,28347615). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2013 | - - |
Likely pathogenic, criteria provided, single submitter | research | Suna and Inan Kirac Foundation Neurodegeneration Research Laboratory, Koc University | Mar 31, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 24, 2020 | The p.Thr11Met variant in C19orf12 has been identified in at least 13 individuals (9 consanguinous homozygous individuals and 2 compound heterozygous individuals) with neurodegeneration with brain iron accumulation (NBIA) and segregated with disease in at least 5 affected members of 4 families (Hartig 2001 PMID 21981780, Schulte 2013 PMID 23436634, Gore 2016 PMID 27801611, Olgiati 2017 PMID 28347615, Alavi 2020 PMID 31970231). It has also been reported as Pathogenic by multiple laboratories in ClinVar (Variation ID 31156) and was identified in 0.004% (1/24194) African chromosomes and 0.001% (1/128668) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org/). This variant falls in noncoding regions of the most abundantly expressed C19orf12 transcripts and functional studies assessing its impact are not available. Additionally, computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal recessive NBIA. ACMG/AMP Criteria applied: PP1_Strong, PM3, PM2_Supporting, BP4. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The C19orf12 c.32C>T (p.Thr11Met) variant, which has been described as one of the most common variants associated with mitochondrial membrane protein-associated neurodegeneration, has been identified in a homozygous state in nine individuals and in a compound heterozygous state in three individuals (Hartig et al. 2011; Deschauer et al. 2012; Dezfouli et al. 2012; Dogu et al. 2013; Tschentscher et al. 2015). The variant was absent from 750 control chromosomes (Hartig et al. 2011) and has not been reported in the 1000 Genomes Project, the Exome Sequencing Project, or the Exome Aggregation Consortium. It has been suggested that the variant may be associated with a later age of onset since it affects only the longer isoform of the protein (Tschentscher et al. 2015). Based on the evidence, the variant is classified as pathogenic for mitochondrial membrane protein-associated neurodegeneration. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 30, 2015 | The T11M variant in the C19orf12 gene has been reported in the homozygous or compound heterozygousstate in multiple individuals with neurodegeneration with brain iron accumulation (Hartig et al., 2011;Schulte et al., 2013). Several individuals with a homozygous T11M variant exhibited early adulthood onsetof dystonia, spasticity, progressive dementia, and psychiatric disorders, including one individual with aParkinson-like phenotype (Tschentscher et al., 2015). The T11M substitution was not observed inapproximately 6100 individuals of European and African American ancestry in the NHLBI ExomeSequencing Project, indicating it is not a common benign variant in these populations. The T11M variant isa non-conservative amino acid substitution, which is likely to impact secondary protein structure as theseresidues differ in polarity, charge, size and/or other properties. Another missense variant in a nearbyresidue (D18G) has also been reported in the Human Gene Mutation Database in association withneurodegeneration with brain iron accumulation (Stenson et al., 2014), supporting the functional importanceof this region of the protein. We interpret T11M as a pathogenic variant. - |
Hereditary spastic paraplegia 43 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 01, 2023 | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 11 of the C19orf12 protein (p.Thr11Met). This variant is present in population databases (rs397514477, gnomAD 0.004%). This missense change has been observed in individuals with autosomal recessive neurodegeneration with brain iron accumulation (PMID: 21981780, 23278385, 23436634, 25592411). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 31156). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. For these reasons, this variant has been classified as Pathogenic. - |
Abnormality of iron homeostasis Pathogenic:1
Pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
Cadd
Benign
Dann
Benign
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T
M_CAP
Benign
D
MetaRNN
Uncertain
D
MetaSVM
Benign
T
MutationAssessor
Benign
N
MutationTaster
Benign
N;N;N;N
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Benign
T
Sift4G
Benign
T
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at